CTI BioPharma Corp. (CTIC) Stock Analysis

What CTI BioPharma Corp. does

CTI BioPharma Corp. is a biopharmaceutical company dedicated to the discovery, advancement, and commercialization of innovative, targeted treatments for blood cancers within the United States. Its key product is VONJO (pacritinib), an oral kinase inhibitor currently under investigation, specifically designed to target JAK2, FLT3, IRAK1, and CSF1R for the management of adult patients with myelofibrosis. The company holds licensing and collaboration agreements with Teva Pharmaceutical Industries Ltd., SBIO Pte Ltd., and Baxalta. Established in 1991 and based in Seattle, Washington, CTI BioPharma Corp. was previously known as Cell Therapeutics, Inc., adopting its current name in May 2014.

Key metrics

ETFs linked to CTIC

Broad-market and Healthcare sector ETFs an investor holding CTI BioPharma Corp. is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CTIC fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for CTI BioPharma Corp.?

CTI BioPharma Corp. trades under the ticker CTIC on NASDAQ.

Which exchange is CTIC listed on?

CTIC is listed on NASDAQ.

What sector does CTI BioPharma Corp. operate in?

CTI BioPharma Corp. is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CTIC in a portfolio?

PortView shows CTIC's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.